Vyleesi (Bremelanotide) Dosage
The recommended dosage of Vyleesi is 1.75 mg administered subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. 1
Standard Dosing Regimen
- Administer 1.75 mg subcutaneously using the prefilled autoinjector pen in either the abdomen or thigh 1
- Timing: At least 45 minutes before anticipated sexual activity 1, 2, 3
- The optimal window for administration has not been fully characterized, so patients may adjust timing based on their individual response to duration of effect and tolerability of adverse reactions like nausea 1
Critical Dosing Restrictions
- Do not administer more than one dose within 24 hours - consecutive doses within 24 hours have not been studied for efficacy and may increase risk of additive blood pressure effects 1, 3
- Do not exceed 8 doses per month - more frequent dosing increases risk of focal hyperpigmentation and prolonged periods of elevated blood pressure 1, 3
- Few patients in phase 3 trials received more than 8 doses monthly, so safety data beyond this frequency are limited 1
Administration Technique
- Self-administered via prefilled autoinjector pen 1
- Visually inspect the solution before administration - discard if cloudy, discolored, or contains visible particles 1
- The solution should be clear 1
Discontinuation Criteria
- Discontinue Vyleesi after 8 weeks if the patient reports no improvement in symptoms 1, 3
- This 8-week trial period allows adequate time to assess therapeutic benefit 3
Important Safety Considerations
- Contraindicated in patients with uncontrolled hypertension or known cardiovascular disease 1
- Vyleesi transiently increases systolic blood pressure by up to 6 mmHg and diastolic blood pressure by up to 3 mmHg, peaking 2-4 hours post-dose, with effects typically resolving within 12 hours 1
- Heart rate decreases by up to 5 beats per minute with each dose 1
- Blood pressure should be well-controlled before initiating therapy and monitored periodically during treatment 1